Healthcare Sector Investing: A Guide for HNW Investors

Healthcare is one of the few sectors that combines genuine defensive characteristics with meaningful long-term structural growth. Demand for healthcare does not disappear in recessions — people get ill regardless of economic conditions — yet the sector also benefits from powerful long-term tailwinds: ageing populations in developed and middle-income countries, rising chronic disease prevalence, and continuing medical innovation. For these reasons, healthcare consistently attracts interest from investors seeking a balance between capital preservation and growth.

However, healthcare is not monolithic. The sector encompasses four distinct sub-sectors — pharmaceuticals, biotechnology, medical technology (medtech), and healthcare services — each with a meaningfully different risk profile, business model, valuation approach, and set of investment considerations. This guide examines each sub-sector in detail and discusses portfolio construction for healthcare exposure.

Important: Healthcare investments involve sector-specific risks including clinical trial failures, regulatory rejection, patent expiry, and pricing pressure from governments and insurers. The value of investments can fall as well as rise. This guide is for information only and does not constitute financial advice.

Why Healthcare Has Defensive Characteristics

The healthcare sector's defensive reputation stems from several structural features:

Non-discretionary demand: Patients cannot easily defer treatment for serious conditions based on economic conditions. Pharmaceutical sales, hospital admissions, and medical device usage are largely decoupled from consumer confidence cycles.

Government and insurer-backed revenue: A significant proportion of global healthcare revenue is paid by governments, public health systems, or private insurers rather than individuals. This provides relative payment security, though it also introduces regulatory and pricing risk.

Low cyclicality: Healthcare earnings have historically shown lower correlation with the economic cycle than sectors such as industrials, consumer discretionary, or commodities. In portfolio construction, this can provide a stabilising effect during downturns.

This defensiveness is relative, not absolute. Healthcare companies face their own specific shocks — regulatory rejections, generic competition, patent expiry — that can cause sharp share price falls even during bull markets. And within healthcare, biotechnology is one of the most volatile segments of the entire equity universe.

Sub-Sector 1: Pharmaceuticals

Business model: Large pharmaceutical companies (known as "big pharma") discover, develop, manufacture, and sell branded medicines protected by patents. Once a patent expires, generic drug manufacturers can produce identical medicines at a fraction of the cost, dramatically reducing revenue from that product.

Valuation approach: Big pharma companies are typically valued on price-to-earnings ratios and dividend yield, reflecting their relatively predictable cash flow profiles between patent expiries. Investors also focus on the pipeline — the portfolio of drugs in development — as a leading indicator of future revenue.

Key risks:

Patent cliff: The most significant recurring risk in pharmaceuticals is the patent cliff — the period during which a company's major patented medicines lose exclusivity and face generic competition. Companies that fail to replace lost revenue with new products can face significant earnings pressure. This is a predictable risk; patent expiry dates are public knowledge, and investors should monitor how well-covered a company's revenue profile is.

Pricing and reimbursement: Pharmaceutical pricing is subject to government and insurer negotiation in virtually every market. In the US — historically the most lucrative pharmaceutical market — the Inflation Reduction Act (2022) introduced Medicare drug price negotiation for the first time, placing downward pressure on US pharmaceutical revenues. In Europe, health technology assessment (HTA) bodies determine which drugs are reimbursed at what price. Companies that cannot demonstrate cost-effectiveness relative to existing treatments face reimbursement rejection or steep discounts.

Regulatory risk: Even late-stage drug approvals can be rejected by regulators (FDA in the US, EMA in the EU, MHRA in the UK). Failed approvals cause significant share price falls.

Key companies: Johnson & Johnson, Pfizer, Roche, Novartis, AstraZeneca, GSK, Sanofi, Eli Lilly, Bristol-Myers Squibb, Merck. UK-listed examples include AstraZeneca and GSK.

Dividend culture: Many large pharmaceutical companies pay substantial, progressive dividends, making them attractive for income-oriented investors. GSK and AstraZeneca are notable UK-listed dividend payers.

Sub-Sector 2: Biotechnology

Business model: Biotechnology companies develop medicines using biological processes — working with living organisms, cells, or their products rather than chemical synthesis. Biotech ranges from small pre-revenue companies in clinical trials to large, profitable enterprises such as Amgen, Gilead, and Regeneron.

Valuation approach: Pre-revenue biotech companies are typically valued on the probability-weighted net present value (NPV) of their pipeline, discounted for clinical trial success rates. This makes valuation highly speculative and sensitive to both binary trial outcomes and interest rate changes (longer-duration cash flows are more sensitive to discount rate movements).

Key risks:

Clinical trial risk: Drug development has very high failure rates. Historically, only around 12% of drugs entering Phase 1 clinical trials eventually receive regulatory approval. Each failed trial can destroy a significant proportion of a small biotech's market capitalisation overnight. Diversification — either through a basket of biotech stocks or via a fund — is important for managing this binary risk.

Financing risk: Pre-revenue biotechs depend on equity capital markets and venture capital to fund research. When market sentiment turns negative or interest rates rise, smaller biotechs may struggle to raise capital, leading to share dilution or failure.

Acquisition dependency: Many small biotechs have business models that depend on eventual acquisition by large pharmaceutical companies. If the M&A market for biotech slows, this exit route may not materialise on expected terms.

Key companies and funds: Amgen, Gilead, Regeneron, BioNTech, Moderna (for larger, profitable biotechs). For small-cap and development-stage exposure, specialist biotech funds — including the Worldwide Healthcare Trust and Biotech Growth Trust (both UK-listed investment trusts) — offer diversification that is difficult to achieve through individual stock selection.

Sub-Sector 3: Medical Technology (Medtech)

Business model: Medtech companies design, manufacture, and sell medical devices, diagnostic equipment, and related technology. Products range from implantable devices (pacemakers, hip replacements, coronary stents) to imaging equipment (MRI, CT scanners), surgical robots, diagnostics (blood tests, genetic sequencing), and digital health tools.

Valuation approach: Medtech companies are typically valued on price-to-earnings and enterprise value/EBITDA multiples. Established medtech companies with recurring revenue from device implants and reagent consumables tend to command premium valuations due to the sticky, predictable nature of their revenue streams.

Key risks:

Product liability: Medical devices can cause patient harm, and product liability litigation — particularly in the US — can generate substantial costs. High-profile examples include mesh device litigation and metal-on-metal hip implant claims.

Regulatory approvals: Medical devices require regulatory clearance (510(k) or PMA in the US, CE marking in the EU, UKCA in the UK). Changes to regulatory pathways — the EU's Medical Device Regulation (MDR) significantly tightened device approvals from 2021 onwards — can delay product launches.

Hospital budget cycles: Capital equipment purchases (imaging, surgical robots) are subject to hospital capital budgeting and are more cyclical than pharmaceutical consumables.

Key companies: Medtronic, Abbott, Boston Scientific, Becton Dickinson, Intuitive Surgical (surgical robots), Danaher (diagnostics), Thermo Fisher Scientific, Siemens Healthineers, Philips Healthcare, Stryker.

Sub-Sector 4: Healthcare Services

Business model: Healthcare services companies operate hospitals, clinics, pharmacies, care homes, and related services. They are intermediaries between patient needs and clinical care, generating revenue from service fees paid by governments, insurers, or individuals.

Valuation approach: Healthcare services companies are typically valued on EV/EBITDA and price-to-earnings, with significant attention to bed capacity, occupancy rates, and reimbursement rates.

Key risks:

Reimbursement changes: Government decisions on NHS funding (in the UK), Medicare/Medicaid reimbursement rates (in the US), or equivalent systems elsewhere directly affect revenue and margin. This makes healthcare services companies significantly exposed to political risk.

Staffing costs: Healthcare is labour-intensive and faces structural shortages of skilled staff — nurses, physicians, care workers — in most developed markets. Wage inflation and agency staffing costs can significantly compress margins.

Private vs. public dynamics: In the UK, private hospital groups (Spire, Ramsay Health Care) benefit from NHS waiting lists driving private pay and NHS outsourcing, but are also subject to NHS policy changes that could redirect patient flows.

Key companies: HCA Healthcare (US, the world's largest hospital operator), UnitedHealth Group, CVS Health, Humana (US managed care), Fresenius (Europe), Spire Healthcare (UK-listed), NMC Health (cautionary example — governance failure in 2020).

The Ageing Demographics Tailwind

The most powerful long-term driver of healthcare demand is demographics. By 2050, according to UN projections, approximately 1.6 billion people globally will be over 65, up from around 760 million in 2023. Developed markets — Japan, Italy, Germany, South Korea, the UK — already have ageing profiles that structurally increase healthcare spending per capita.

Older populations have higher prevalence of chronic conditions — cardiovascular disease, diabetes, cancer, dementia, osteoporosis — that generate sustained demand for pharmaceuticals, devices, and services. This structural tailwind does not guarantee superior investment returns (the market prices known trends), but it provides a long-duration growth driver that distinguishes healthcare from many other sectors.

Global Healthcare ETFs

For investors seeking broad healthcare exposure, several ETFs provide diversified access:

• iShares Global Healthcare ETF (IUHC): Tracks the MSCI World Health Care Index; broad global pharmaceutical, biotech, medtech, and services exposure
• Xtrackers MSCI World Health Care ETF (XDWH): Similar global healthcare exposure, low cost
• iShares S&P 500 Health Care Sector ETF (IUHS): US-focused; heavier pharma and managed care weighting
• SPDR MSCI Europe Health Care ETF: European healthcare exposure; heavier pharmaceutical and medtech weighting relative to services
• L&G Global Pharmaceuticals Index Trust: Concentrated pharmaceutical exposure

UK-listed investment trusts — including Worldwide Healthcare Trust and Biotech Growth Trust — offer actively managed exposure with varying sub-sector tilts.

Portfolio Construction Considerations

In a diversified portfolio, healthcare typically serves a dual role: defensive anchor and structural growth exposure. The appropriate allocation depends on risk appetite, existing portfolio composition, and income requirements.

Key construction decisions include:

• Large-cap pharma vs. biotech: More stability vs. higher growth and volatility
• Global vs. US-centric: The US is the largest and most profitable pharmaceutical market but carries greater pricing regulation uncertainty
• Hedged vs. unhedged currency exposure: Most major healthcare companies generate significant USD revenues; sterling investors face currency risk in unhedged exposures
• Active vs. passive: Biotech especially lends itself to active management due to the importance of pipeline analysis and clinical trial expertise

How Global Investments Can Help

Healthcare is a complex sector where investment success often depends on understanding clinical, regulatory, and competitive dynamics that are not apparent from financial statements alone. At Global Investments, we access specialist healthcare research and select funds managed by teams with deep sector expertise — including private equity healthcare strategies for clients seeking exposure beyond listed markets.

We help clients determine the right balance across pharmaceutical, biotech, medtech, and services, and the appropriate global allocation, given their broader portfolio objectives. Contact our team to discuss healthcare exposure within your investment strategy.

This guide is for information purposes only and does not constitute financial advice. The value of investments can fall as well as rise. Healthcare investments carry sector-specific risks including clinical trial failures and regulatory changes. Always seek qualified professional advice before making investment decisions.